Clinical Study

Time Course of Changes in Simulated Keratometry and Total Corneal Refractive Power after Corneal Collagen Cross-Linking for Progressive Keratoconus

Masahide Takahashi,1 Kazutaka Kamiya2, Yusuke Kono,1 and Nobuyuki Shoji1

1Department of Ophthalmology, Kitasato University, Japan
2School of Allied Health Sciences, Kitasato University, Japan

Correspondence should be addressed to Kazutaka Kamiya; kamiyak-ky@umin.ac.jp

Received 17 March 2018; Revised 22 July 2018; Accepted 1 August 2018; Published 12 August 2018

Academic Editor: Mitsuru Nakazawa

Copyright © 2018 Masahide Takahashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To assess the simulated keratometry (Sim K) and the total corneal refractive power (TCRP) in eyes undergoing conventional corneal cross-linking (CXL). Methods. This study comprised 20 eyes of 20 keratoconic patients (14 men and 6 women; median age (25th and 75th percentile), 26.5 (21.8, 38.0) years) who underwent CXL. The Sim K and TCRP were measured with a rotating Scheimpflug system (Pentacam HR, Oculus), preoperatively and 1, 3, 6, and 12 months postoperatively. Results. The values of Sim K were 52.65 (46.00, 55.70), 52.45 (45.85, 56.88), 51.70 (45.78, 55.83), 51.40 (45.68, 56.80), and 51.25 (46.08, 56.15) D preoperatively and 1, 3, 6, and 12 months postoperatively, respectively. The corresponding figures of TCRP were 52.10 (45.48, 55.08), 51.30 (45.18, 55.20), 50.95 (45.15, 54.50), 50.00 (45.18, 55.08), and 49.80 (45.48, 54.15) D, respectively. The variances of the Sim K and TCRP data were not statistically significant (p=0.994 and p=0.970, respectively, Kruskal–Wallis test). The Sim K was significantly larger than the TCRP before CXL and at 1, 3, 6, and 12 months after CXL (p<0.001, Wilcoxon signed-rank test). Conclusions. Not only the Sim K but also TCRP was decreased by approximately 1 D after CXL. The Sim K readings may overestimate the TCRP, even after CXL for progressive keratoconus.

1. Introduction

Keratoconus is a progressive noninflammatory disorder characterized by anterior protrusion and thinning of the cornea, deteriorating visual performance with time. The corneal cross-linking (CXL) by means of riboflavin and ultraviolet light has been well established as a therapeutic approach to halt the progression of the disease in eyes with keratoconus [1, 2]. However, we usually evaluated the progression of the disease mainly in terms of the keratometric readings obtained by using a corneal topographer or an autokeratometer, both of which were routinely used in daily practice. These keratometric readings are theoretically calculated based on the assumption that the ratio of the anterior and posterior curvatures remained constant. Moreover, the CXL treatment itself may induce a change in the anterior and posterior corneal curvatures and subsequently alter the actual total corneal power for keratoconus. Hence, these simulated keratometric readings (Sim K) may overestimate the actual total corneal refractive power (TCRP), in not only pre- but also post-CXL treated eyes. However, to the best of our knowledge, the time course of changes in the true corneal power has not so far been extensively investigated in eyes having CXL treatment. It may give us intrinsic insights into the precise changes in the true corneal power, which are essential to determine the precise intraocular lens (IOL) power and/or rigid gas permeable (RGP) lens power in such patients in daily practice. The purpose of the current study is to retrospectively assess the time course of changes in the Sim K and TCRP, in a cohort of progressive keratoconic subjects who underwent conventional CXL treatment.

2. Materials and Methods

2.1. Study Population. The study protocol was registered with the University Hospital Medical Information Network
Clinical Trial Registry (0000306599). This retrospective study comprised 20 eyes of 20 keratoconic patients (14 men and 6 women; median age (25th and 75th percentile), 26.5 (21.8, 38.0) years) who underwent standard CXL treatment for progressive keratoconus, and who completed a 1-year follow-up, with good quality scans of corneal tomography measured with a rotating Scheimpflug imaging instrument (Pentacam HR™, Oculus, Wetzlar, Germany). Diagnosis of keratoconus was conducted by one experienced clinician (K.K.) with evident findings characteristic of keratoconus (e.g., corneal topography with asymmetric bow-tie pattern with or without skewed axes) and at least one keratoconus sign (e.g., stromal thinning, conical protrusion of the cornea at the apex, Fleischer ring, Vogt striae, or anterior stromal scar) on slit-lamp examination [3]. Progression was defined as an increase in the maximum keratometric reading of at least 1 diopter (D), or a worsening of corrected visual acuity with an increase of astigmatism ≥1 D confirmed in at least 2 examinations during the preceding 6 to 12 months before treatment. We did not perform CXL in eyes with thinner corneas (the thinnest point < 400 mm), in consideration of the safety issues of corneal endothelial cell density. Eyes with pellucid marginal degeneration, other corneal diseases, and previous ocular trauma or surgery were excluded from the study. The patients were recruited in a continuous cohort. The patients who wore rigid gas permeable and soft contact lenses were asked to stop wearing them for 3 and 2 weeks before this evaluation, respectively, in order to exclude the effect of wearing contact lenses [4, 5]. We randomly enrolled only one eye per subject for statistical analysis. The sample size in the present study offered 80.7% statistical power at the 5% level in order to detect a 1-D difference in the corneal refractive power, when the SD of the mean difference was 1.5 D. This retrospective review of the data was approved by the Institutional Review Board at Kitasato University and followed the tenets of the Declaration of Helsinki. Our Institutional Review Board waived the requirement for informed consent for this retrospective study.

2.2. Corneal Cross-Linking. The standard CXL technique was applied in accordance with the Dresden protocol [1]. In brief, after topical anesthesia, we removed the corneal epithelium from a central circular area of 8 mm in diameter using a blunt spatula. Then, we topically administrated riboflavin 0.1% solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrated to the anterior chamber solution every 2 minutes for 30 minutes and confirmed that adequate riboflavin was penetrate...
### Table 1: Preoperative demographics of the study population in eyes undergoing corneal cross-linking for progressive keratoconus.

| Preoperative demographics (median (25th and 75th percentile)) |    |
|---------------------------------------------------------------|----|
| Number of eyes                                                | 20 |
| Male:Female                                                   | 14:6|
| Age                                                          | 26.5 (21.8, 38.0) years |
| Uncorrected visual acuity (logMAR)                           | 1.00 (0.70, 1.40) |
| Corrected visual acuity (logMAR)                             | 0.40 (0.10, 0.52) |
| Manifest spherical equivalent                                 | -2.31 (-6.00, -0.69) D |
| Manifest cylinder                                             | 3.00 (1.25, 5.00) D |
| Sim K                                                         | 52.65 (46.00, 55.70) D |
| TCRP                                                          | 52.10 (45.48, 55.08) D |

logMAR: logarithm of the minimal angle of resolution, D: diopter, Sim K: simulated keratometry, TCRP: total corneal refractive power.

**Figure 1:** Changes in corrected visual acuity 1 year after corneal cross-linking (CXL).

3.4. **Corneal Thickness.** Time course of changes in central corneal thickness is shown in Figure 3. The variance of the central corneal thickness data was not statistically significant (p=0.194, Kruskal–Wallis test). Multiple comparisons demonstrated no significant differences between measurements made before CXL and at 1, 3, 6, and 12 months after CXL (p=1.000, 0.994, 0.983, and 0.992, respectively). The Sim K was significantly larger than the TCRP before CXL and at 1, 3, 6, and 12 months after CXL (p<0.001, Wilcoxon signed-rank test). This difference between the Sim K and TCRP tended to be larger with time.

3.5. **Endothelial Cell Density.** Endothelial cell density was not significantly changed, from 2738 (2491, 2906) cells/mm$^2$ preoperatively to 2651 (2425, 2887) cells/mm$^2$ postoperatively (p=0.140).

3.6. **Adverse Events/Complications.** No eyes showed any progression of the disease at any time after CXL. Three eyes (15%) showed a transient mild haze formation at 1 to 3 months after CXL. Otherwise, we found no vision-threatening complications such as severe haze formation, severe corneal endothelial cell loss (≥10%), or infection.

4. **Discussion**

In the present study, our findings showed that there were no significant changes in Sim K and TCRP before and after CXL treatment, but that both Sim K and TCRP were decreased by approximately 1 D one year after CXL treatment. Vinciguerra et al. reported that the average keratometry showed a mean reduction of 1.06 D 2 years after CXL [6]. Doors et al. described that no significant keratometric changes were observed at 3, 6, and 12 months postoperatively compared with preoperatively, after an initial steepening of maximal keratometry values [7]. Lamy et al. found a mean reduction in Sim K of 0.41, 0.41, 0.33, and 0.61 D after 3 months, 6 months, 1 year, and 2 years of CXL treatment, respectively [8]. The current findings of a reduction in the mean keratometry were comparable with these previous findings [6–8]. Although uncorrected visual acuity was not significantly changed, corrected visual acuity was significantly improved after CXL treatment. The CXL treatment may improve the
irregular shape of the cornea, resulting in a decrease in higher-order aberrations and a subsequent improvement in correct visual acuity in the study population. As far as we can ascertain, this is the first study to assess the time course of the actual corneal power in eyes undergoing CXL for progressive keratoconus. Our findings also showed that the Sim K was significantly larger than the TCRP not only preoperatively, but also postoperatively, and that the difference between the Sim K and TCRP tended to be larger with time. It is suggested that the Sim K readings may overestimate the TCRP even after CXL for progressive keratoconus, especially when longer time has passed after CXL.

It is still challenging to accurately determine IOL power for post-CXL treated eyes in daily practice. We assume that it is clinically helpful for understanding the precise change in corneal power after CXL for keratoconus. The overestimation of the corneal refractive power may lead to the selection of the lower IOL power, resulting in a hyperopic refractive error in eyes with keratoconus. Actually, Leccisotti et al. stated that the IOL exchange due to imprecise IOL power occurred in 32% after refractive lens exchange in keratoconic patients [9]. Watson et al. stated that the use of actual keratometric readings can result in a large hyperopic error for severe keratoconus [10]. Park et al. reported that a hyperopic shift was noted since localized corneal posterior elevation is not reflected in conventional IOL power calculation for posterior keratoconus [11]. Camps et al. reported that the use of a single value of the keratometric index for the calculation of the total corneal power in keratoconus has been shown to be imprecise, leading to inaccuracies in the detection and classification of this corneal condition [12]. Furthermore, the CXL treatment may alter both anterior and posterior corneal curvatures and thus result in the actual total corneal power in keratoconic eyes. We should be aware that there is a need for
optimizing IOL power when we calculated IOL power using the conventional keratometric readings, not only before CXL but also after CXL.

This study has at least two limitations. One is that we determined the Sim K and TCRP on the 3.0-mm ring only using the Scheimpflug imaging system, because this measurement is considered to be simple and easy to quantitatively grasp corneal refractive power for keratoconus. However, anterior segment optical coherence tomographer may have advantages over the Scheimpflug camera in terms of the accuracy as well as the reproducibility, especially in keratoconic eyes with corneal opacity [13]. Another limitation is that we did not evaluate the repeatability of the corneal power measurements in this cohort. However, we previously confirmed the good repeatability of the Sim K and TCRP measurements for keratoconus [5]. Additionally, the Scheimpflug system has been shown to have an excellent repeatability of the corneal curvature measurements even in keratoconic eyes [14, 15]. Hence, we believe that the instrument offers clinically reasonable repeatability even in the assessment of corneal refractive power in post-CXL keratoconic eyes.

In conclusion, our findings indicate that CXL was effective in halting the progression of the disease in eyes with keratoconus, and both Sim K and TCRP were decreased by approximately 1 D after CXL. The Sim K readings may overestimate the TCRP, even after CXL for progressive keratoconus. We believe that this information was simple, but helpful for understanding the actual corneal power in post-CXL treated eyes, especially when we calculate the precise IOL power and/or RGP lens power in such patients.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Disclosure
The authors alone are responsible for the content and writing of the paper.

Conflicts of Interest
The authors have declared that no conflicts of interest exist.

References
[1] G. Wollensak, E. Spoerl, and T. Seiler, “Riboflavin/ultraviolet-a-induced collagen crosslinking for the treatment of keratoconus,” American Journal of Ophthalmology, vol. 135, no. 5, pp. 620–627, 2003.
[2] G. Wollensak, “Crosslinking treatment of progressive keratoconus: new hope,” Current Opinion in Ophthalmology, vol. 17, no. 4, pp. 356–360, 2006.
[3] Y. S. Rabinowitz, “Keratoconus,” Survey of Ophthalmology, vol. 42, no. 4, pp. 297–319, 1998.
[4] K. Kamiya, R. Ishii, K. Shimizu, and A. Igarashi, “Evaluation of corneal elevation, pachymetry and keratometry in keratoconic eyes with respect to the stage of Amsler-Krumeich classification,” British Journal of Ophthalmology, vol. 98, no. 4, pp. 459–463, 2014.
[5] K. Kamiya, K. Shimizu, A. Igarashi, and T. Miyake, “Assessment of anterior, posterior, and total central corneal astigmatism in eyes with keratoconus,” American Journal of Ophthalmology, vol. 160, no. 5, pp. 851–857.e1, 2015.
[6] P. Vinciguerra, E. Albé, S. Trazza, T. Seiler, and D. Epstein, “Intraoperative and postoperative effects of corneal collagen cross-linking on progressive keratoconus,” JAMA Ophthalmology, vol. 127, no. 10, pp. 1258–1265, 2009.
[7] M. Doors, N. G. Tahzib, F. A. Eggink, T. T. J. M. Berendschot, C. A. B. Webers, and R. M. M. A. Nuijts, “Use of anterior segment optical coherence tomography to study corneal changes after collagen cross-linking,” American Journal of Ophthalmology, vol. 148, no. 6, pp. 844.e2–851.e2, 2009.
[8] R. Lamy, C. F. Netto, R. G. Reis et al., “Effects of corneal cross-linking on contrast sensitivity, visual acuity, and corneal topography in patients with keratoconus,” Cornea, vol. 32, no. 5, pp. 591–596, 2013.
[9] A. Leccisotti, “Refractive lens exchange in keratoconus,” Journal of Cataract & Refractive Surgery, vol. 32, no. 5, pp. 742–746, 2006.
[10] M. P. Watson, S. Anand, M. Bhogal et al., “Cataract surgery outcome in eyes with keratoconus,” British Journal of Ophthalmology, vol. 98, no. 3, pp. 361–364, 2014.
[11] D. Y. Park, D. H. Lim, T.-Y. Chung, and E.-S. Chung, “Intraocular lens power calculations in a patient with posterior keratoconus,” Cornea, vol. 32, no. 5, pp. 708–711, 2013.
[12] V. J. Camps, D. P. Piñero, E. Caravaca-Arenes, D. De Fez, R. J. Pérez-Cambrodí, and A. Artola, “New approach for correction of error associated with keratometric estimation of corneal power in keratoconus,” Cornea, vol. 33, no. 9, pp. 960–967, 2014.
[13] N. M. Samy El Gendy, Y. Li, X. Zhang, and D. Huang, “Repeatability of pachymetric mapping using Fourier domain optical coherence tomography in corneas with opacities,” Cornea, vol. 31, no. 4, pp. 418–423, 2012.
[14] J. C. Reddy, C. J. Rapuano, J. R. Cater, K. Suri, P. K. Nagra, and K. M. Hammersmith, “Comparative evaluation of dual Scheimpflug imaging parameters in keratoconus, early keratoconus, and normal eyes,” Journal of Cataract & Refractive Surgery, vol. 40, no. 4, pp. 582–592, 2014.
[15] R. Montalbán, J. L. Alió, J. Javaloy, and D. P. Piñero, “Intrasubject repeatability in keratoconus-eye measurements obtained with a new Scheimpflug photography-based system,” Journal of Cataract & Refractive Surgery, vol. 39, no. 2, pp. 211–218, 2013.
